We are pleased to present this whitepaper to you, Deal Theory: A Biopharma Deal Maker’s Approach to Maximizing Strategic Value, to share some best practices that will help companies achieve better results through the right partnership transactions.

Based on recent acquisition activity by two of the largest pharmaceutical companies, it seems as if the historical orthodoxy that great biopharma companies are made from the inside out may be losing...

Overview Biotech companies are attracted to licensing deals for a variety of important reasons: 1) to provide an alternative source of capital from the licensee to fund R&D and commercial operations including, but not limited to, advancement of the asset(s) in...

How Does a Smart Deal Maker “Play” This Region and Optimize the Capital Raising and Strategic Deal Making Opportunities? Authors: Hayato Watanabe, SVP, Head of Asia Koji Hirabata, Associate Stefanie Gan, Analyst Although their biopharma ecosystem dynamics...

At Locust Walk, we are often tasked with addressing complex strategic business issues for our biopharma clients. Perhaps one of the most common dilemmas is how best to optimize a given company’s clinical development strategy to maximize value. Specifically, many...

Emerging biopharma companies with promising lead candidates in late-stage trials are often faced with a fundamental decision: go-it-alone (self-commercialize) or secure a strategic partner to support development and commercialization. It is a classic strategic choice...